2.830EUR-1.05%Mkt Cap: 99.83M EURP/E: —Last update: 2026-06-01
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activiti…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap99.83M EUR
Enterprise Value—
Revenue (TTM)4.10M EUR
Gross Profit534.00K EUR
Net Income (TTM)-5.55M EUR
Revenue/Share—
Last Price2.830 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0012616852
Valuation
P/E (Trailing)—
P/E (Forward)-9.66
PEG—
EV/EBITDA—
EV/Revenue—
P/S24.61
P/B18.22
EPS (TTM)-0.16
EPS (Forward)-0.30
52W Range
1.17040% of range5.290
52W High5.290 EUR
52W Low1.170 EUR
Profitability
Gross Margin13.14%
Oper. Margin-160.02%
EBITDA Margin-131.10%
Profit Margin-136.60%
ROE-123.01%
ROA-42.32%
Growth
Revenue Growth-10.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.93M EUR
CapEx (TTM)242.00K EUR
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.84
Current Ratio—
Quick Ratio—
Book Value/Sh0.1570 EUR
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)10.50 EUR
Target Range10.00 EUR – 11.00 EUR
# Analysts2
Ownership
Shares Out.35.27M
Float—
Insiders35.55%
Institutions4.48%
Technical
SMA 503.529 (-19.8%)
SMA 2003.615 (-21.7%)
Beta0.58
S&P 52W Chg27.94%
Avg Vol (30d)121.43K
Avg Vol (10d)211.21K
Technical Indicators
RSI (14)25.6
MACD-0.1311
MACD Signal-0.0551
MACD Hist.-0.0760
BB Upper3.916 EUR
BB Middle3.447 EUR
BB Lower2.979 EUR
BB Width27.18%
ATR (14)0.1962 EUR
Vol Ratio (20d)1.07x